ImmunoGen, Inc. Reports First Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update
Linkedin

ImmunoGen, Inc. Reports First Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update

Ascó : Spain | Oct 26, 2012 at 6:15 AM PDT
Source: The Motley Fool
XX XX
Views: Pending
 
Reports First Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update Marketing applications submitted for trastuzumab emtansine (T-DM1) in the US and Europe. Meaningful clinical data expected to be reported in coming year for ImmunoGen compounds, T-DM1, and other partner compounds.... FULL ARTICLE AT The Motley Fool
 
  • Clear
  • Share:
  • Share
  • Clear
  • Clear
  • Clear
  • Clear
 
  • Credibility
  • Wait... Flag
 
 
Advertisement
 

More From Allvoices

Most Commented Reports



Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc. 2008-2014. All rights reserved. Powered by PulsePoint.